Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Pediatric Hematology/Oncology
•
Medical Oncology
•
Testicular Cancer
•
NCI-CCC Tumor Board Question
•
AYA
•
Johns Hopkins
•
NCI-CCC GU Tumor Board Question
Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?
Answer from: Medical Oncologist at Academic Institution
No.
Sign in or Register to read more
12828
Related Questions
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
Would you be more inclined to offer adjuvant therapy to a patient who is age>60 with stage 1B seminoma?
When will you consider doing a biopsy of a potential metastatic site (lymph node, lung/visceral) for testicular cancer after orchiectomy?
What is your preferred mode of vascular access for testicular cancer regimens?
Is there a preferred chemotherapy regimen for chemo-mobilization prior to HDCT for a patient with NSGCT with prior BEP and TIP?
What is your preferred choice of therapy for first-line treatment of a patient with good, intermediate, or poor risk stage III nonseminomatous germ cell tumor if the patient is truly cisplatin-ineligible?
What are your top takeaways from ASCO GU 2025?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
Do you hold or dose modify chemotherapy with BEP or EP for severe cytopenia or renal injury when treating testicular cancer in the curative setting?